Shearman & Sterling represented Boston Scientific in a definitive agreement to acquire Axonics Inc., a publicly traded medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction, for a cash price of $71 per share, reflecting an equity value of approximately $3.7 billion. The transaction was announced on Jan. 8, 2024 in a press release.

Boston Scientific, a global medical technology leader for more than 40 years, expects to complete the transaction in the first half of 2024, subject to customary closing conditions.

The Team